Perigon Wealth Management’s Krystal Biotech KRYS Stock Holding History

Perigon Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,970	Closed	-$2.21M	–	1364
2025 Q4	$2.21M	Buy	8,970 +41	+0.5%	+$8.63K	0.04%	349
2025 Q3	$1.58M	Buy	8,929 +31	+0.3%	+$4.64K	0.03%	406
2025 Q2	$1.22M	Buy	8,898 +407	+5%	+$59.8K	0.03%	423
2025 Q1	$1.53M	Buy	8,491 +202	+2%	+$34K	0.04%	362
2024 Q4	$1.2M	Buy	8,289 +123	+2%	+$21.8K	0.03%	401
2024 Q3	$1.49M	Buy	8,166 +13	+0.2%	+$2.51K	0.04%	335
2024 Q2	$1.5M	Buy	8,153 +1,700	+26%	+$285K	0.04%	292
2024 Q1	$1.15M	Buy	6,453 +1,579	+32%	+$219K	0.03%	344
2023 Q4	$605K	Buy	4,874 +791	+19%	+$87.7K	0.02%	451
2023 Q3	$474K	Buy	4,083 +2,324	+132%	+$284K	0.02%	456
2023 Q2	$207K	Buy	+1,759	New	+$180K	0.01%	726

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perigon Wealth Management's KRYS Position: Q1 2026 in Review

Perigon Wealth Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 8,970 shares — an estimated $2.21M sold.

Perigon Wealth Management first reported a position in KRYS in Q2 2023 and held it in 11 quarters. The position peaked at $2.21M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Perigon Wealth Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
Perigon Wealth Management sold 8,970 Krystal Biotech shares in Q1 2026, an estimated $2.21M.
Perigon Wealth Management first reported a position in Krystal Biotech in Q2 2023 and held it in 11 quarters.
Perigon Wealth Management's Krystal Biotech position peaked at $2.21M in Q4 2025.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.